Erich L Grimm

USPTO Granted Patents = 26 (Patent Applications = 4)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 6.0

ph-index = 8

Forward Citations = 215(Granted Patents)

Location History:

Kirkland, CA (2001)
Quebec, CA (2000 - 2003)
Baie d'Urfe, CA (1993 - 2014)

Company Filing History:

12 out of 212

Merck Frosst Canada, Inc.

patents

6 out of 76

Merck Frosst Canada & Co.

Merck Sharp + Dohme Corp.

patents

6. 1 out of 1

Merk Frosst Canada & Co.

patent

7. 1 out of 217

Actelion Pharmaceuticals Ltd

patents

8. 1 out of 1

Merck Forsst Canada & Co.

patent

Years Active: 1993-2014

Loading Chart...

26 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 8889714 - 3,4-substituted piperidine derivatives as renin inhibitors (2014-11-18),

2. 8076359 - Renin inhibitors (2011-12-13),

3. 8063105 - Renin inhibitors (2011-11-22),

4. 7960409 - Pharmaceutical phenylquinoline and chromen-2-one triazole compounds (2011-06-14),

5. 7553973 - Pharmaceutical compounds (2009-06-30),

6. 7439260 - 7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors (2008-10-21),

7. 6699856 - Pyrazinones, compositions containing such compounds and methods of use (2004-03-02),

8. 6552168 - Gamma-ketoacid tetrapeptides as inhibitors of caspase-3 (2003-04-22),

9. 6525025 - Gamma-ketoacid dipeptides as inhibitors of caspase-3 (2003-02-25),

10. 6444811 - Pyrazinones, compositions containing such compounds and methods of use (2002-09-03),

11. 6225288 - Gamma-ketoacid dipeptides as inhibitors of caspase-3 (2001-05-01),

12. 6222048 - Diaryl-2-(5H)-furanones as Cox-2 inhibitors (2001-04-24),

13. 6169188 - (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors (2001-01-02),

14. 6133292 - Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective (2000-10-17),

15. 6071954 - (methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 (2000-06-06),

Sure, I can help with that. Let's start with the article structure.

Title: The Innovative Path of Erich L Grimm: Pioneering Renin Inhibitors in Baie d'Urfe

Introduction:

Erich L Grimm, a prolific inventor based in Baie d'Urfe, Canada, has made significant contributions to the field of pharmaceuticals with a remarkable portfolio of 26 patents. His groundbreaking work in developing renin inhibitors has paved the way for novel treatments in cardiovascular events and renal insufficiency.

Latest Patents:

Grimm's recent patents showcase his expertise in 3,4-substituted piperidine derivatives as renin inhibitors and disubstituted piperidinyl renin inhibitor compounds. These inventions not only demonstrate his innovative approach but also highlight his dedication to improving healthcare outcomes for patients.

Career Highlights:

Having worked at esteemed companies such as Merck Frosst Canada, Inc. and Merck & Company, Inc., Grimm has honed his skills and expertise in pharmaceutical research and development. His experience in these reputable organizations has undoubtedly shaped his inventive capabilities and fueled his passion for creating novel pharmaceutical solutions.

Collaborations:

Throughout his career, Grimm has collaborated with exceptional professionals in the field, including Cameron Black and Petpiboon Prasit. These collaborations have not only enriched his projects but also fostered a culture of innovation and teamwork, leading to the successful development of cutting-edge pharmaceutical compounds.

Conclusion:

Erich L Grimm's journey as an inventor has been marked by a relentless pursuit of innovation and excellence. His groundbreaking patents and collaborations stand as a testament to his unwavering commitment to advancing healthcare through pioneering pharmaceutical solutions. Baie d'Urfe can proudly claim Grimm as one of its own, a visionary inventor shaping the future of pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.